Form 8-K - Current report:
SEC Accession No. 0001193125-25-045567
Filing Date
2025-03-04
Accepted
2025-03-04 16:01:15
Documents
15
Period of Report
2025-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d876730d8k.htm   iXBRL 8-K 28006
2 EX-10.1 d876730dex101.htm EX-10.1 27064
6 GRAPHIC g876730dsp_11.jpg GRAPHIC 10539
  Complete submission text file 0001193125-25-045567.txt   198279

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20250228.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20250228_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20250228_pre.xml EX-101.PRE 11265
17 EXTRACTED XBRL INSTANCE DOCUMENT d876730d8k_htm.xml XML 3645
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 25704044
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)